Restatement: Recognized impairment loss of 7,645 million won on investment in subsidiary Puriogen, reducing retained earnings and equity by the same amount.
Consolidated operating loss: Q1 2025 operating loss of 4,330 million won, widening from 2,963 million won in Q1 2024.
Consolidated net loss: Q1 net loss of 5,798 million won (vs 5,784 million won in Q1 2024).
Consolidated revenue: Q1 10,821 million won, down 68% from 34,178 million won YoY.
Debt ratio: 133.1%, net debt ratio 94.1%, indicating weak financial structure.
Cash and short-term financial instruments: 173.8 billion won; total borrowings 103.9 billion, bonds 14.8 billion, total financial liabilities 151.1 billion.
Holds 202,129 treasury shares; no additional buyback or cancellation plans.
Ongoing patent infringement lawsuit in China; management expects no material impact on finances.
KOSDAQ Filing Information
Filing: [Correction of Description] Quarterly Report (2025.03)